Medicare launches pilot to cover GLP-1 obesity drugs for seniors at $50 monthly
A new federal pilot program will allow eligible Medicare beneficiaries to obtain GLP-1 medications for obesity at a $50 co-pay per month, beginning in July and running through the end of 2027.
Starting Wednesday, Medicare will offer a pilot program that covers GLP-1 drugs used for obesity treatment at a $50 co-pay for eligible seniors. The initiative, authorized by the Department of Health and Human Services, will run until Dec. 31, 2027 and is limited to beneficiaries who meet specific body-mass-index and health-condition criteria.
Under the program, the government has negotiated a price of $250 per month for a supply of drugs such as Eli Lilly's Foundayo, Novo Nordisk's Wegovy and Zepbound, and Novo Nordisk's Wegovy Pill. Patients will pay the $50 co-pay, which does not count toward their annual deductible. Prior authorization is required; clinicians must document that patients meet the BMI thresholds (≥35, or 30-35 with certain heart or kidney conditions, or 27-30 with pre-diabetes or cardiovascular history) and do not have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease.
"These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost," said Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid.
"GLP-1s can be life-changing for patients managing obesity and related conditions," said Chris Klomp, director of Medicare at the U.S. Department of Health and Human Services.
The program is expected to affect up to 3.8 million beneficiaries, according to a Kaiser Family Foundation analysis of 2023 Part D enrollment data. Eligible prescriptions can be filled at retail pharmacies or through the manufacturers’ direct-to-consumer mail-order services.